Additional Metadata
Keywords calcium, cyclic AMP, cystic kidney, hypercalciuria, kidney stones, kidney tubule, polycystic kidney disease, risk factors, polycystic kidney, autosomal dominant, tolvaptan, kidney calculi
Persistent URL dx.doi.org/10.2215/CJN.07610520, hdl.handle.net/1765/128750
Journal Clinical Journal of the American Society of Nephrology
Rights No Subscription.
Citation
Zietse, R. (2020). ADPKD, tolvaptan, and nephrolithiasis risk. Clinical Journal of the American Society of Nephrology, 15(7), 923–925. doi:10.2215/CJN.07610520